Impact of Sitagliptin on the Progression of Coronary Atherosclerosis in Diabetes Patients with Angina Pectoris

Impact of Sitagliptin on the Progression of Coronary Atherosclerosis in Diabetes Patients with Angina Pectoris - Sitagliptin and coronary atherosclerosis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011263

Enrollment

Registered

2013-08-01

Start date

2013-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic patients with angina pectoris scheduled underwent percutaneous coronary intervention with drug eluting stent.

Interventions

Sitagliptin treatment group

Clinical investigators will initiate sitagliptin treatment after PCI Sitaglitptin non-treatment group

Clinical investigators will treat with oral antidiabetic agents except for sitagliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Type2 diabetes 2)Stable angina pectoris with scheduled PCI 3)PCI with drug-eluting stent 4)informed consent for participation in the study

Exclusion criteria

Exclusion criteria: 1)Acute myocardial infarction and cardiogenic shock 2)PCI for left main trunk 3)Type1 diabetes 4)Severe ketosis and coma with in 6 months 5)Severe renal deficiency 6)Hemodyalysis 7)Treatment with immunosuppresant 8)Treatment with pioglitazone, glynide and insulin 9)Treatment with DPP4 except for sitagliptin 10)Hypersensitivity to sitagliptin 11)Pregnant and possible pregnat women 12)Malignancy 13)Judged as ineligible by clinical investigators

Design outcomes

Primary

Measure	Time frame
Changes in plaque volume of coronary atherosclerosis assessed by intravascular ultrasound and plaque characteristics assessed by optical coherence tomography	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026